Sylentis is a biopharmaceutical company focused on developing RNAi-based treatments for ophthalmological diseases, particularly targeting conditions like dry eye syndrome, macular degeneration, and ocular allergies.

Sylentis

siRNA Technology

SYLENTIS | 6,459 followers on LinkedIn. Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Andreas Segerros

Triple Master in Risk Prevention, Quality and Environment Management. European Quality Formation

Marina Alonso Sanchez

Responsable de producción en Sylentis/ Docente MASTER Industria Farmacéutica

Elsa Rodríguez Puerta

Production Technician in Sylentis

Bruno Barbón González

SYLENTIS

This week, SYLENTIS will be participating in the 20th Annual Meeting Oligonucleotide Therapeutics Society. Please visit our booth!! Oligonucleotide Therapeutics Society #oligonucleotidos #OTS2024 #RNAi #oligotherapeutic

👉 Ana Isabel Jiménez , General Director, and Eva García Fernández , Business Development Manager, are representing SYLENTIS and the #OLIGOFASTX consortium at the Oligonucleotide Therapeutics Society being held these days in Montreal, Canada. Sharing experiences in a meeting of the leading experts in #oligonucleotide development. 🧬 📌 https://cstu.io/d1610c #fundedbyCDTI

OLIGOFASTX

The 2024 Nobel Prize in Physiology or Medicine has been awarded today to Victor Ambros and Gary Ruvkun for their discovery of microRNA and its role in post-transcriptional gene regulation. They identified microRNA, a novel class of small RNA molecules that play a crucial role in gene expression control. Their seminal discovery was reported in two papers published back-to-back in Cell in 1993 (Lee, Feinbaum and Ambros, 1993; Wightman, Ha and Ruvkun, 1993). It is now known that the human genome encodes over a thousand microRNAs, adding a whole new layer to the complexity of gene regulation. Their remarkable discovery has opened an unexpected and revolutionary dimension to our understanding of biology. Congratulations to the honorees! And of course, a big thank you for their invaluable contributions to RNA research and gene regulation. 👏 For the second year in a row, RNA takes center stage at the Nobel Prize in Medicine. At Sylentis, we proudly celebrate the growing awareness of this vital molecule for life, around which our work revolves. #oligonucleotides #RNA #microRNA #siRNA #Sylentis #NobelPrize 👉 https://lnkd.in/eFU7DuZf

🔸Innovations in Oligonucleotide Therapeutics Manufacturing to Responsibly Meet Future Demand🔸 Join us at the Oligonucleotide Therapeutics Society Congress 2024 for our poster ( #P076 ) presentation on Monday, October 7, from 5:00 pm to 8:00 pm! 📍 We look forward to engaging with fellow professionals and discussing how we can collectively drive innovation in oligonucleotide manufacturing. Don’t miss it! #Oligonucleotides #Innovation #Sustainability #Manufacturing #CDMO #SylentisCDMO #OTS2024

OTS Congress 2024 is close!! The 20th Annual Meeting of the Oligonucleotide Therapeutics Society will be held from October 6 to 9 in Montreal, Canada. 📆 Sylentis will be there at booth 4-15. 📧🗣 Contacts: Ana Isabel Jiménez and Eva García Fernández 🎯 Know Sylentis CDMO: Oligonucleotides manufacturing – Therapeutic Oligos – GMP Solutions – RNA&DNA – Extensive expertise – Customized Services See you there!

It is estimated that 1 in 3,000 – 4,000 of the world’s population suffers from retinitis pigmentosa, and it is the leading cause of total blindness. At Sylentis and within the Oligofastx project, we work to develop an oligo-based new therapy for this Ophthalmological disease #WorlRetinitisPigmentosaDay2024 #Oligonucleotides #NewTherapies

We had a fantastic time at FARMAFORUM 2024 !! It was a pleasure connecting with so many professionals and companies in the pharma sector, and we look forward to building on the exciting conversations and opportunities that were discussed. We would like to thank the organizers for giving my colleague Verónica Ruz the opportunity to participate in the clinical research forum. Looking forward to next year’s edition! SYLENTIS

Ana Isabel Jiménez

📆 Today at FARMAFORUM 2024 ... We were thrilled to participate in the roundtable discussion “Risk-Based Quality Management in Clinical Trials: Innovations and Practical Improvements” 🙌 Our colleague Veronica Ruz , along with the other panelists, engaged in a fascinating discussion, sharing valuable insights and exploring key issues on this important topic. Thank you to all the participants, organizers, and attendees! #ClinicalResearchForum #ClinicalResearch #Sylentis #Quality

SYLENTIS is part of the consortium leading SECRETed Project H2020 . Don't miss the chance to learn more about this exciting European project at FARMAFORUM 2024 💧 #H2020 #Sustainability

Asiste a la Mesa Redonda 👉Implementación y Desafíos de la Gestión de Calidad Basada en Riesgos ( #RBQM ) en #EnsayosClínicos : Innovaciones y Mejoras Prácticas El evento forma parte de la agenda de la Feria FARMAFORUM 2024 que se celebrará el 25 y 26 de septiembre en IFEMA, Madrid La Mesa Redonda será moderada por Marta Valverde Collazo , responsable del Área de Investigación Clínica, KONEXIO BIOTECH cuenta con la participación de: 👩💼 Ana Maria Tello Miller , Clinical Monitoring Unit Head, Sermes CRO 👩💼 Dr. Leire Zúñiga, PharmD, PhD , CEO Pharmity ; Chief Quality Officer (CQO), Qlarix Healthcare Solutions 👩💼 Veronica Ruz , responsable de Asuntos Regulatorios y QA, Director Técnico, SYLENTIS 👩💼Yolanda Lara, Associate Director, Project Management, Global CRO; Vocal de Investigación Clínica, AEFI - Asociación Española de Farmacéuticos de la Industria 👨💼 Antonio Llamas , Associate Director, Clinical Operations Late Phase, Gilead Sciences 👨💼 Carlos Palacios Associate Director, Oncology, Clinical Operations, Gilead Sciences Será el 26.09.2024 a partir de las 12:30h en la Sala: Farmaforum / Clinical Research Forum en el Pabellón 9 de IFEMA. Registro online👉 https://lnkd.in/eDUss4d9

Gisela M. Bühl

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Head of Regulatory Affairs

Veronica Ruz

Jose María Fernandez Sousa Faro

Founder & CEO

Anne-Marie Bleau

Clinical Operations Manager

Spain Companies With Less Than $1B in Revenue (Top 10K)

Madrid Companies With Less Than $10M in Revenue

Madrid Companies With Less Than $50M in Revenue (Top 10K)

Spain Companies With Fewer Than 1000 Employees (Top 10K)

Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action.

The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.

Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company



Madrid

Spain

Europe

Spanish RNAi Drug Could Work Better Than Antihistamines for Eye Allergies

Mexico

North America

Indonesia

Asia

Sylentis is a biotechnology company focused on the research, development, and commercialization of innovative RNA therapeutics for the treatment of ophthalmological diseases.  Sylentis's self-described mission is to improve patients' lives through the development of new treatments.

news impact assignment basic	general
public peers	general	Nov 13, 2024 10:39 AM	ef8ccf3d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 13, 2024 10:39 AM	dcd6d00d
crunchbase trigger	general	Nov 13, 2024 10:39 AM	f753cd64
crunchbase profile	general	Nov 13, 2024 8:09 PM	95364385
li profile	general	Nov 13, 2024 10:39 AM	be73af27
translate crunchbase fundingrounds	general	Nov 13, 2024 8:58 PM	4ee80fae
peers	general	Nov 13, 2024 10:39 AM	60074b52
news basic	general	Nov 13, 2024 10:39 AM	8637a2f1
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SYLE

COM:SYLENTIS

Sylentis